Paper Details

  1. Home
  2. Paper Details

Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials.

Author: AmentaFrancesco, ColucciLuisa, FasanaroAngiola M, MolinoIvana, TrainiEnea

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Acetylcholinesterase (AChE)/cholinesterase (ChE) inhibitors (Is) and memantine are approved treatments for mild-moderate and moderate-severe Alzheimer's disease (AD), respectively. High doses of the AChE-I donepezil are approved for moderate-severe AD in the USA, and the combination of AChE/ChE-Is plus memantine has been proposed for AD at this stage.
Paper Details　
Original Abstract of the Article :
Acetylcholinesterase (AChE)/cholinesterase (ChE) inhibitors (Is) and memantine are licensed for symptomatic treatment of mild-moderate and moderate-severe forms of Alzheimer's disease (AD), respectively. High doses of the AChE-I donepezil were licensed in the USA for moderate-severe AD, and the asso...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830825/

データ提供：米国国立医学図書館（NLM）

Memantine, Donepezil, and Alzheimer's Disease: A Quest for Effective Treatment

In the realm of neurodegenerative disorders, we find ourselves continually seeking effective treatments for Alzheimer's disease (AD). This study delves into the efficacy of memantine, donepezil, and their combination in treating moderate-severe AD, exploring the potential for these medications to alleviate symptoms and improve patient outcomes. The authors embark on a journey through the literature, reviewing clinical trials to assess the effectiveness of these treatments.

Memantine, Donepezil, and Their Combination: A Review of Clinical Trials

The authors meticulously review clinical trials investigating the efficacy of memantine, donepezil, and their combination in treating moderate-severe AD. This comprehensive analysis, like a desert expedition meticulously mapping a vast landscape, aims to provide a comprehensive understanding of the therapeutic potential of these medications.

Navigating the Treatment Landscape: Exploring Effective Options for Alzheimer's Disease

This study, like a beacon in the desert of Alzheimer's research, provides valuable insights into the treatment options available for moderate-severe AD. It underscores the importance of personalized approaches, considering individual patient needs and potential benefits and risks of various treatment strategies.

Dr.Camel's Conclusion

This study, like a caravan navigating the challenging landscape of Alzheimer's disease research, offers a comprehensive review of clinical trials investigating the efficacy of memantine, donepezil, and their combination. It underscores the ongoing quest for effective treatments for AD, highlighting the importance of personalized approaches based on individual patient needs and a thorough understanding of the potential benefits and risks associated with various treatment options.

Date :
  1. Date Completed 2014-07-17
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

24288512

DOI: Digital Object Identifier

PMC3830825

Related Literature

Article Analysis
・Effective treatment of alzheimer's disease
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.